Tier 2 — strong

Betaine homocysteine methyltransferase (BHMT)-dependent remethylation pathway in human healthy and tumoral liver

Hélène Pellanda
Clinical chemistry and laboratory medicine 2013 51(3):617-621

Bibliography

PubMed
PMID 23449526
DOI
10.1515/cclm-2012-0689
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignHuman tissue and cell-line study
ModelHuman liver tissue and HepG2 cells
SampleHuman liver tumor samples and HepG2 cells; 6 tumors assessed for protein expression
InterventionBHMT expression and activity in tumor versus non-tumor material
DurationCross-sectional laboratory analysis
EndpointsBHMT expression; Liver cancer metabolism

What the study showed, in plain terms

Published in 2013, this source examined mechanistic and clinical reviews. Design: Human tissue and cell-line study. Sample/model: Human liver tumor samples and HepG2 cells; 6 tumors assessed for protein expression. The exposure or intervention was BHMT expression and activity in tumor versus non-tumor material. Follow-up or treatment period: Cross-sectional laboratory analysis.

BHMT expression and activity were markedly reduced in the investigated tumor material and HepG2 cells.

Despite review indexing, the abstract describes primary tissue/cell work. Cause versus consequence is unresolved and betaine treatment was not tested.

Continue with TMG Data Center

Continue with TMG, Methylation and MTHFR: Understanding the Evidence

Key findings

  • BHMT expression and activity were markedly reduced in the investigated tumor material and HepG2 cells.
  • The recorded outcome domains were BHMT expression; Liver cancer metabolism.
  • The result applies to the tested exposure: BHMT expression and activity in tumor versus non-tumor material; Cross-sectional laboratory analysis.

What this study can and cannot tell us

  • Despite review indexing, the abstract describes primary tissue/cell work. Cause versus consequence is unresolved and betaine treatment was not tested.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Association of choline and betaine levels with cancer incidence and survival: A meta-analysis
Jiyoung Youn et al. · Clinical nutrition (Edinburgh, Scotland) · 2019
Tier 4
Choline and betaine consumption lowers cancer risk: a meta-analysis of epidemiologic studies
Shanwen Sun et al. · Scientific reports · 2016
Tier 4
The association between dietary intakes of methionine, choline and betaine and breast cancer risk: A systematic review and meta-analysis
Heleen Van Puyvelde et al. · Cancer epidemiology · 2023
Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024
Tier 4
Beneficial Effects of Betaine: A Comprehensive Review
Madan Kumar Arumugam et al. · Biology · 2021
Tier 4
Betaine in human nutrition
Stuart A S Craig et al. · The American journal of clinical nutrition · 2004

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology